A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT07277413
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-03-04Est. Completion: 2028-04-30
Enrollment target: 260 participants Locations- Providence Medical Foundation, Santa Rosa, California, United States
- Johns Hopkins Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- BRCR Global-Coral Springs, Coral Springs, Florida, United States
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
- Nebraska Cancer Specialists, Omaha, Nebraska, United States
- START Astera, LLC, East Brunswick, New Jersey, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- START Dallas Fort Worth, Fort Worth, Texas, United States
- MD Anderson, Houston, Texas, United States
- NEXT Oncology Houston, Houston, Texas, United States
- NEXT Oncology Dallas, Irving, Texas, United States
- START Mountain Region, LLC, West Valley City, Utah, United States
- NEXT Oncology Virginia, Fairfax, Virginia, United States
Other microbiome trials you might be interested in
Lung AdenocarcinomaLung Large Cell CarcinomaLung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of p…
Buena Park, United StatesEst. completion Jun 30, 2027
Lung AdenocarcinomaLung Adenosquamous CarcinomaLung Non-Small Cell Carcinoma
Swedish Cancer Institute, Seattle, Washington, United StatesStage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without…
Phoenix, United StatesCompleted Dec 12, 2030
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination …
Duarte, United StatesEst. completion Mar 4, 2025